1. AB0743 Low rates of major adverse cardiac events, malignancies, and serious infections in patients with psoriasis and psoriatic arthritis treated with apremilast for ≥156 weeks: pooled analysis from the esteem and palace 1-3 phase 3 trials. (15th June 2017) Authors: Kavanaugh, A; Augustin, M; Lespessailles, E; Papp, KA; Paris, M; Chen, R; Gladman, DD; Pariser, DM; Peris, K Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1314 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0469 Integrated efficacy analysis of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis. (15th June 2017) Authors: Nash, P; Coates, LC; Fleischmann, R; Papp, KA; Gomez-Reino, JJ; Kanik, KS; Wang, C; Wu, J; Hendrikx, T; Ports, WC Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 951 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Dose Response and Pharmacokinetics of Tofacitinib (CP‐690, 550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis. (22nd May 2013) Authors: Tan, H; Gupta, P; Harness, J; Wolk, R; Chapel, S; Menter, A; Strober, B; Langley, RG; Krishnaswami, S; Papp, KA Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 2:Number 5(2013) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗